

Split Fill Oral Oncology

Overview

The Split Fill program minimizes drug waste and reduces health plan costs by identifying specialty drugs associated with early discontinuation or dose modifications. Each drug is evaluated using evidence-based criteria to determine the frequency and duration of the split fill requirements.

Drug List

- Includes generic and alternative formulations

Cancer – Oral Drug List

Afinitor® (everolimus)	Exkivity™ (mobocertinib)	Lynparza® (olaparib)
Akeega™ (niraparib and abiraterone acetate)	Gavreto® (pralsetinib)	Lytgobi® (futibatinib)
Ayvakit™ (avapritinib)	Gleevec® (imatinib)	Nerlynx® (neratinib)
Balversa® (erdafitinib)	Iclusig® (ponatinib)	Nexavar® (sorafenib)
Bosulif® (bosutinib)	Inlyta® (axitinib)	Nubeqa® (darolutamide)
Cabometyx® (cabozantinib)	Inrebic® (fedratinib)	Odomzo® (sonidegib)
Calquence® (Acalabrutinib)	Iressa® (gefitinib)	Ogsiveo™ (nirogacestat)
Cometriq® (cabozantinib)	Jakafi® (ruxolitinib)	Retevmo™ (selpercatinib)
Copiktra® (duvelisib)	Jaypirca™ (pirtobrutinib)	Rezlidhia™ (olutasidenib)
Daurismo™ (glasdegib)	Krazati® (adagrasib)	Rozlytrek® (entrectinib)
Erivedge® (vismodegib)	Lenvima® (lenvatinib)	Rubraca® (rucaparib)
	Lorbrena® (lorlatinib)	Sprycel® (dasatinib)
	Lumakras™ (sotorasib)	Sutent® (sunitinib)



Regence BlueShield
serves select counties in the state of Washington and is an Independent
Licensee of the Blue Cross and Blue Shield Association

Regence BlueShield
1800 Ninth Avenue | Seattle, WA 98101

Effective 2/2024
© 2024 Regence BlueShield

Regence complies with applicable Federal and Washington state civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, sex, gender identity or sexual orientation. ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-888-344-6347 (TTY: 711). 注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 1-888-344-6347 (TTY: 711).

Tagrisso® (osimertinib)

Talzenna® (talazoparib)

Tarceva® (erlotinib)

Targretin® (bexarotene)

Tasigna® (nilotinib)

Tepmetko® (tepotinib)

Verzenio® (abemaciclib)

Vitrakvi® (larotrectinib)

Vizimpro® (dacomitinib)

Vonjo™ (pacritinib)

Votrient® (pazopanib)

Welireg™ (belzutifan)

Xalkori® (crizotinib)

Xospata® (gilteritinib)

Xpovio® (selinexor)

Xtandi® (enzalutamide)

Yonsa® (abiraterone)

Zejula® (niraparib)

Zolinza® (vorinostat)

Zykadia® (ceritinib)

Zytiga® (abiraterone)